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lian Guidelines [1] those regimens studied 
in randomized controlled trials and shown 
to have durable virologic efficacy, favoura-
ble tolerability profiles, and ease of use are 
defined as first choice. Alternative are effec-
tive treatments that present some potential 
disadvantages if compared with preferred re-
gimens. They may be a valid choise in certain 
situations and based on individual patient 
needs. Some other regimens are classified as 
“not recommended ” because of reduced vi-
rologic activity, lack of supporting data from 
INTRODUCTION
The correct moment and regimen for starting 
HIV antiretroviral therapy has been debated 
since the concept of HAART (Highly Acti-
ve Antiretroviral Therapy) was introduced. 
In general, regimen selection should be in-
dividualized based on a number of factors, 
including co-morbidity conditions, resistan-
ce, potential adverse drug effects, drug in-
teractions, pregnancy, CD4 count, tropism 
assay and specific tests, and administration 
convenience. Very briefly, according to Ita-
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ABSTRACT
OBJECTIVE: The gradual increase of persons living with HIV, mainly due to the reduced mortality achieved with effective 
antiretroviral therapies, calls for increased rationality and awareness in health resources consumption also during the early 
illness phases. Aim of this work is the estimation of the budget impact related to the variation in backbone prescribing 
trends in naïve patients.
METHODS: Target population is the number of patients starting antiretroviral therapy each year, according to the Italian 
HIV surveillance registry, excluding patients receiving non-authorized or non-recommended regimens. We modeled 3-year 
mortality and durability rates on a dynamic cohort, basing on international literature. A prevalent patients analysis has also 
been conducted, for which the model is fed by a closed cohort consisting of all the patients without experience of virologic 
failure. The aim of this collateral analysis is to estimate the difference in current annual expenditures if the past prescription 
trends for patients starting therapy would have led to the evaluated hypothetical scenarios. Current Italian market shares of 
triple regimens containing first-choice or alternative backbones (tenofovir/emtricitabine, abacavir/lamivudine, tenofovir/
lamivudine and zidovudine/lamivudine) are compared to three hypothetical scenarios (base-case, minimum and maximum) 
in which increasing shares of patients eligible to abacavir/lamivudine start first line treatment with this backbone. Annual 
cost for each regimen comprises drugs acquisition under hospital pricing rules, monitoring exams and preventive tests, 
valued basing on regional reimbursement tariffs.
RESULTS: According to current prescribing trends, in the next three years about 13,000 patients starting HIV therapy will 
receive tenofovir/emtricitabine (83% of the target population), and minor portions other regimens (9% abacavir/lamivu-
dine, 8% zidovudine/lamivudine). Patients that would be eligible to abacavir/lamivudine are 1.5, 4.5 and 6 thousand more 
than those presently treated according to the three hypothetical scenarios, leading to a cumulative saving of 850 thousand, 
2.4 million and 3.3 million euro, respectively. If in the past the same modification of first line prescription trend was 
adopted, the annual current cost saving would vary from 922 thousands to 7.3 million euro. Most of this amount is due to 
reduced acquisition costs and, secondarily, to lower monitoring needs.
CONCLUSION: Where patient features don’t force the choice of the backbone, abacavir/lamivudine prescription may 
induce substantial savings, allowing the release of resources needed to manage more complicated/advanced cases.
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aim we built a decision-analytic Budget Im-
pact Model (BIM) that estimates the number 
of treatment-naive HIV patients that every 
year start HAART, their distributions among 
first choice (and alternative) regimens in the 
real context, and the expenditure changes of 
hypothetical prescription trend modifications 
to show the amount that the National Health 
Service could potentially save and dedicate 
to the portion of complex HIV cases.
METHODS
Model characteristics
The presented BIM is programmed to answer 
two questions: what is the financial impact 
on the Italian National Health Service of 
changing the current backbone prescription 
trend for patients starting HAART? How 
much could be annually saved (or paid) if, in 
the past, the first line prescription trend had 
been different? In both cases, the third drug 
market share is kept constant. To answer the 
first question, we ran the analysis on an open 
cohort of incident to therapy patients, over 
a three year time horizon. This incidence 
with accumulation methodology is the most 
appropriate to simulate chronic illnesses on 
medium-long time horizons, according to the 
international Budget Impact Analysis guide-
line [5]. The second question is answered by 
means of the prevalent simulation, in which 
the model is fed by a closed cohort consisting 
of all the patients receiving HAART therapy 
in Italy that have not experienced virologic 
failure yet (first line + switched for tolerabi-
lity patients) over a single year time horizon. 
In both simulations, the very same cohort is 
virtually assigned to the current scenario, that 
represents the real patient distribution among 
selected regimens, and to the hypothetical 
scenario, representing the prescription va-
riation we would like to evaluate. The cost 
ascribed to each scenario comprises pharma-
ceutical and laboratory costs. The analysis 
considers both the national and the regional 
contexts.
Incident patient pool simulation
Patient flow
For the first year, the model is fed with the 
pool of patients that annually begin HAART 
(incident to therapy); the next year the cohort 
consists of alive and persistent first year-pa-
tients, to which the new cases pool is added. 
The same reasoning is applied for the third 
year. One of the most challenging tasks re-
quired to define the patient flow is the estima-
te of the annual rate of HAART starting. It is 
a fact that only a fraction of new HIV diagno-
ses is immediately followed by therapy start. 
large clinical trials, or other factors, such as 
toxicities, administration schedule, etc.
An initial HAART regimen generally con-
sists of two nucleoside reverse transcriptase 
inhibitors (NRTIs) as backbone and a third 
drug consisting of a protease inhibitor (PI), 
preferably “boosted” with ritonavir, or a 
non-nucleoside reverse transcriptase inhibi-
tor (NNRTI). More recent third drug classes, 
like INSTI (integrase strand transfer inhibi-
tors) are very effective, but more expensive 
compared to the older ones; so their use is 
still limited. The two backbones recommen-
ded as first choice in the Italian Guideline 
are tenofovir/emtricitabine, in fixed combi-
nation with efavirenz or not, and abacavir/
lamivudine, for viral loads <100.000 copies 
per millilitres. The combination of tenofovir/
lamivudine (non-available as one-pill co-for-
mulation) and of lamivudine/zidovudine are 
considered as alternative backbones. Dida-
nosine-based backbones are defined “not re-
commended” strategies. Guidelines suggest 
to also take in account the presence of speci-
fic factors when taking backbone decisions: 
renal and bone co-morbidities advise against 
tenofovir prescription, while abacavir may 
be employed only in HLA-B*5701 negati-
ve patients. Three randomized trials have 
compared abacavir/lamivudine and tenofo-
vir/emtricitabine [2-4] on almost 3,000 HIV 
patients. Two of these involved treatment-
naive patients [3,4]. Two trials found simi-
lar efficacy, while Sax and colleagues found 
better efficacy with the tenofovir-based regi-
men in those patients with > 100,000 copies/
ml [4]. All the trials had the strong limita-
tions of not having excluded patients positi-
ve for HLA-B*5701 antigen, which media-
tes hypersensitivity event, and of not having 
evaluated bone mineral density.
Reviews of real prescription data and expert 
opinion indicate that often it is the third drug 
choice that drives regimen selection in the 
clinical management of HIV patients when 
starting HAART. This behaviour is mainly 
due to resistance issues, prescribing expe-
rience or spending containment. A common 
problem of both clinical and administrative 
hospital decision makers is indeed the need 
to combine clinical efficacy and economic 
affordability; one way to get to this objective 
is targeting the prescription choice in order 
to contain the expense for patients that well 
respond to cheaper treatments and, concur-
rently, save the financial funds for difficult 
patients. We planned to investigate how the 
financial impact of the antiretroviral first line 
treatment in Italy may change as a result of 
a variation in backbone prescription, kee-
ping the third drug choice constant. At this 
77Farmeconomia. Health economics and therapeutic pathways 2013; 14(2) © SEEd All rights reserved
O. Zaniolo, M. Povero, P. Bonfanti, M. Borderi, M. Medaglia
 - First-line therapy;
 - HAART beginning between March 2011 
and February 2012 (to avoid seasonal 
time bias on recorded market shares);
 - First ten regimens for each backbone (of 
which only recommended ones are con-
sidered).
Regimens basing on tenofovir/lamivudine 
in extemporary association (co-formulation 
is not available on the market) is prescribed 
in an undetectable portion of patients in our 
sample of sales. For the Regional analyses, 
However, in the present model we consider 
no difference between HIV incidence and in-
cidence to therapy rates; this choice is based 
on the assumption that both the HIV inciden-
ce and the mean lag between diagnosis and 
therapy beginning are quite constant over the 
short time horizon considered. According to 
this postulation, the portion of patients recei-
ving diagnosis in the past years that begin 
treatment in the year of the analysis is similar 
to that of patients receiving diagnosis in the 
year of analysis that will start the therapy in 
the future. Only first choice and alternative 
regimens are considered: patients starting 
HAART with not recommended/not autho-
rized regimens are excluded from the simu-
lated cohort. The patient flow input data for 
the incident pool simulation are summarized 
in Table I.
New diagnoses incidence rate is taken from 
the national AIDS database updated to 2009 
[6] and applied to current resident popu-
lation of each region [10]. Mortality rate is 
assigned to HIV patients in function of the 
cumulative time in therapy, based on data of 
an european observational multicenter study 
[8]. The persistence in therapy corresponds to 
the durability of the treatment till virologic 
failure; it has been assumed homogeneous 
among regimens and exclusively dependent 
on the time in therapy. This choice is made to 
avoid two confounding effects: the paradox 
effect of inducing higher costs for strategies 
with major durability, and the masking effect 
of producing BIM results influenced not only 
by the cost of the regimen, but also by diffe-
rent numbers of treated patients. We estima-
ted this common persistence rate by means 
of a Bayesian random effects meta-analysis 
on durability data of the main HAART regi-
mens, as collected by Colombo and collea-
gues [9].
Prescription scenarios
Current prescription tendency in Italy for pa-
tients that start HAART is shown in Table II.
It’s estimated based on sales data [7], with 
restriction to:
Input data Source
HIV incidence 
rate (n diagnosis/ 
100.000 
habitants/year)
Italia* 5.68 ISS, 2011 [6]
Piemonte 6.8
Valle d’Aosta 7.9
Lombardia 6.4
Trentino-Alto Adige 4.7
Veneto 4.4
Friuli-Venezia Giulia 2.8
Liguria 6.4
Emilia-Romagna 9.3
Toscana* 5.7
Umbria 4.8
Marche 5.6
Lazio 9.0
Abruzzo 6.0
Molise* 5.7
Campania* 5.7
Puglia 2.9
Basilicata* 5.7
Calabria 1.6
Sicilia 3.2
Sardegna 2.7
Patients excluded for regimen (%) 10.79 IMFO, 2011-2012 [7]
HIV patients 
mortality (%)
After 1 year of therapy 1.70 Murray, 2011 [8]
After 2 years of therapy 2.64
Persistence in 
therapy (%)
After 1 year of therapy 75.5 Elaborated from 
Colombo, 2011 [9]After 2 years of therapy 64.2
Table I. Incident patients analysis: patient flow input data
* Elaborated as average of the regions with available data
Backbone MS RAL DRV/r ATV/r LPV/r EFV NVP fAPV/r
ABC/3TC (%) 8.97 1.47 21.69 49.27 10.17 10.17 5.76 1.47
TDF/FTC (%) 82.98 0.75 25.37 25.96 8.76 38.23* 0.92 0.00
AZT/3TC (%) 8.05 0.00 4.80 8.01 61.36 8.11 16.12 1.60
TDF + 3TC (%) 0.00 - - - - - - -
Weighted mean (%) 0.75 23.38 26.61 13.13 33.29 2.58 0.26
Table II. Incident analysis: current scenario prescription data
3TC = lamivudine; ABC = abacavir; ATV = atazanavir; AZT = zidovudine; DRV = darunavir; EFV = efavirenz; fAPV = fosamprenavir; 
FTC = emtricitabine; LPV = lopinavir; MS = Market Share; NVP = nevirapine; r = ritonavir; RAL = raltegravir; TDF = tenofovir
* Of which 59% co-formulated (Atripla®)
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that are in the first line of treatment or that 
switched therapy for tolerability reasons (no 
virologic failure), with the further exclusion 
of patients receiving regimens composed by 
four or more drugs.
As in the incident pool simulation, only first 
choice and alternative regimens are conside-
red.
Prescription scenarios
The current distribution among first choice 
regimens of the prevalent target population 
(no virologic failure patients) is shown in Ta-
ble V. It’s estimated based on sales data [7], 
considering:
 - First-line treatment + switched for tolera-
bility reasons patients;
 - No time restriction for HAART begin-
ning;
 - First ten regimens for each recommended 
backbone.
Input data Source
Prevalent 
Italian HIV 
patients (n.)
Italia 61,175 IMFO, 2011-2012 [7]
Piemonte 3,820
Valle d’Aosta 60
Lombardia 18,603
Trentino-Alto Adige 642
Veneto 4,059
Friuli-Venezia Giulia 779
Liguria 2,352
Emilia-Romagna 7,235
Toscana 3,861
Umbria 727
Marche 1,377
Lazio 8,656
Abruzzi 575
Molise 71
Campania 1,921
Puglia 2,141
Basilicata 118
Calabria 385
Sicilia 2,275
Sardegna 1,518
Other
No virologic failure patients (%) 70.90 Market survey - Data on file
Patients excluded for regimen (%) 10.00 IMFO, 2011-2012 [7]
Table IV. Prevalent analysis: patient flow input data
data for each backbone are available, but not 
detailed by line of treatment, so these values 
are estimated by matching regional overall 
backbone prescription with the between-lines 
relative frequencies recorded in the National 
setting
Hypothetical scenarios, as previously defi-
ned, represent variations in prescription tren-
ds whose effect we would like to evaluate. 
Four main constraints condition our hypothe-
tical settings:
 - Tenofovir/emtricitabine and abacavir/la-
mivudine are the only two guideline- re-
commended first choice backbones;
 - Their effectiveness has been shown simi-
lar for < 100,000 copies/ml patients;
 - Third drug market shares have to be 
maintained on average constant in the 
two scenarios;
 - Abacavir is not recommended in patients 
positive for HLA-B*5701 allele.
Patients with less than 100,000 copies/ml be-
fore therapy start and negative for HLA-
B*5701 allele are indicated to receive abaca-
vir/lamivudine as backbone (Table III). 
Some observational data show that viral lo-
ads below this threshold are present in about 
70% of treatment-naive patients [11-13]. Re-
cent Italian data [14,15] indicate lower va-
lues (under 50%, assuming a uniform distri-
bution between median and Q3). We 
conservatively assumed a base case scenario 
in which this portion is set to 40%, testing 
the sensitivity of our results to this as-
sumption with minimum and maximum sce-
narios, in which only 20% and up to 50% of 
patients present low viral loads, respectively. 
The prevalence of the allele associated to 
abacavir hypersensitivity is taken from a stu-
dy pooling the results of six multicenter trials 
on its frequency in the patient population, 
measured independently from treatment re-
ceived or previous screening [16]; for our 
country the prevalence resulted equal to 6%. 
Matching these considerations, we con-
structed hypothetical scenarios reported in 
Table III.
Prevalent patient pool
Patient flow
The analysis on the prevalent cohort, as anti-
cipated, aims to estimate how much it would 
annually cost to treat prevalent HIV patients 
never yet experiencing a virologic failure, 
with the hypothetical prescription patterns as 
compared to the real one. It has not the objec-
tive to make future previsions, but to inform 
on the potential difference in annual costs in 
the case in which the prescription trend for 
incident patients accumulating over time had 
been such to observe today the hypothetical 
scenario in the current prevalent first line 
population. The total number of prevalent 
Italian HIV patients is calculated based on 
backbone consumption (Table IV), under the 
assumption that each patient doesn’t receive 
more than one backbone regimen.
Target population is determined by the por-
tion of total prevalent Italian HIV patients 
Backbone – Market Share
ABC/3TC 
(%)
TDF/FTC 
(%)
AZT/3TC 
(%)
TDF + 
3TC (%)
Base-case scenario 37.60 54.35 8.05 0.00
Minimum scenario 18.80 73.15 8.05 0.00
Maximum scenario 47.00 44.95 8.05 0.00
Third drug
RAL 0.75%
DRV/r 23.38%
ATV/r 26.61%
LPV/r 13.13%
EFV 33.29%
NVP 2.58%
fAPV/r 0.26%
Table III. Incident analysis: hypothetical scenarios prescription data
3TC = lamivudine; ABC = abacavir; ATV = atazanavir; AZT = zidovudine; 
DRV = darunavir; EFV = efavirenz; fAPV = fosamprenavir; FTC = emtricitabine; 
LPV = lopinavir; NVP = nevirapine; r = ritonavir; RAL = raltegravir; TDF = tenofovir 
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that are in the first line of treatment or that 
switched therapy for tolerability reasons (no 
virologic failure), with the further exclusion 
of patients receiving regimens composed by 
four or more drugs.
As in the incident pool simulation, only first 
choice and alternative regimens are conside-
red.
Prescription scenarios
The current distribution among first choice 
regimens of the prevalent target population 
(no virologic failure patients) is shown in Ta-
ble V. It’s estimated based on sales data [7], 
considering:
 - First-line treatment + switched for tolera-
bility reasons patients;
 - No time restriction for HAART begin-
ning;
 - First ten regimens for each recommended 
backbone.
Input data Source
Prevalent 
Italian HIV 
patients (n.)
Italia 61,175 IMFO, 2011-2012 [7]
Piemonte 3,820
Valle d’Aosta 60
Lombardia 18,603
Trentino-Alto Adige 642
Veneto 4,059
Friuli-Venezia Giulia 779
Liguria 2,352
Emilia-Romagna 7,235
Toscana 3,861
Umbria 727
Marche 1,377
Lazio 8,656
Abruzzi 575
Molise 71
Campania 1,921
Puglia 2,141
Basilicata 118
Calabria 385
Sicilia 2,275
Sardegna 1,518
Other
No virologic failure patients (%) 70.90 Market survey - Data on file
Patients excluded for regimen (%) 10.00 IMFO, 2011-2012 [7]
Table IV. Prevalent analysis: patient flow input data
Hypothetical scenario inputs follow the same 
reasoning and assumptions of the analysis on 
incident patients: market shares of abacavir/
lamivudine are set on 18.80%, 37.60% and 
47%, respectively for minimum, base-case 
and maximum scenario, with a correspon-
ding switch of patients from tenofovir/emtri-
citabine.
Economical inputs
Cost of each regimen is estimated according 
to the following scheme.
Direct costs = preventive tests + 
Pharmaceutical + Monitoring
Pre-treatment costs
Italian and international guidelines [1,17] 
recommend specific laboratory and clinical 
exams before starting HAART to test the sui-
Backbone MS RAL DRV/r ATV/r LPV/r EFV NVP fAPV/r
ABC/3TC (%) 14.74 1.77 7.15 39.00 14.08 15.69 13.74 8.57
TDF/FTC (%) 76.30 1.88 10.47 22.24 12.18 41.87 7.68 3.68
AZT/3TC (%) 7.30 0.68 1.09 4.43 38.85 10.61 40.59 3.75
TDF + 3TC (%) 1.66 0.00 4.88 19.58 28.45 19.64 20.61 6.84
Weighted mean (%) 1.74 9.20 23.37 14.68 35.36 11.19 4.46
Table V. Prevalent analysis: current scenario prescription data
3TC = lamivudine; ABC = abacavir; ATV = atazanavir; AZT = zidovudine; DRV = darunavir; EFV = efavirenz; fAPV = fosamprenavir; 
FTC = emtricitabine; LPV = lopinavir; MS = Market Share; NVP = nevirapine; r = ritonavir; RAL = raltegravir; TDF = tenofovir
Drug Daily dose Packaging Monthly H cost (€) Source
ABC (Ziagen®) 600 mg 60 tab 300 mg 224.40 LG 2012 [1], PDT 2012 [18]
ABC/3TC (Kivexa®) 1 tab 30 tab 600/300 mg 398.31
ATV (Reyataz®) 300 mg 30 cps 300 mg 332.97
DRV(Prezista®) 800 mg 60 tab 400 mg 348.48
EFV (Sustiva®) 600 mg 30 tab 600 mg 214.50
FTC* (Emtriva®) 200 mg 30 tab 200 mg 161.48 LG 2012 [1], IF 2012 [19]
fAPV (Telzir®) 1,400 mg 60 tab 700 mg 316.14 LG 2012 [1], PDT 2012 [18]
3TC (Epivir®) 300 mg 30 tab 300 mg 86.46
LPV/r (Kaletra®) 800/200 mg 120 tab 200/50 mg 357.72
NVP (Viramune®) 400 mg 60 tab 200 mg 188.10
RTV (Norvir®) 100 mg 84 cps 100 mg 24.90
RTV (Norvir®) 200 gm 84 cps 100 mg 49.94
RAL (Isentress®) 800 mg 60 tab 400 mg 521.40
TDF (Viread®) 245 mg 30 tab 245 mg 276.87
TDF/FTC/EFV (Atripla®) 1 tab 30 tab 245/200/600 mg 653.40
TDF/FTC (Truvada®) 1 tab 30 tab 245/200 mg 438.90
AZT (Retrovir®) 600 mg 60 tab 300 mg 123.75
AZT/3TC (Combivir®) 600/300 mg 60 tab 300/150 mg 313.50
Table VI. Dosage and price of drugs considered in the model
*Not present in [18]
3TC = lamivudine; ABC = abacavir; ATV = atazanavir; AZT = zidovudine; DRV = darunavir; EFV = efavirenz; fAPV = fosamprenavir; FTC = emtricitabine; 
LPV/r = lopinavir;/ritonavir NVP = nevirapine; RAL = raltegravir; RTV = ritonavir; TDF = tenofovir 
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tients receiving abacavir, 3 times/year for 
those receiving a protease inhibitor;
Unit cost for monitoring exams is taken from 
current National and local reimbursement ta-
riffs [20] (Table VII).
RESULTS
Patients results
Every year in Italy, about three thousand pa-
tients are estimated to start HAART, of which 
2,300 stay on the same first line therapy for 
the following year, and about 1,900 for the 
third consecutive year. The incidence with 
accumulation approach leads to the gathering 
of a target population of 7,300 patients, for 
the third year of the analysis. Table VIII sum-
marizes the incident patient flow over time; a 
total of 15,703 patients have been treated for 
1 year. Table IX shows the patient distribu-
tion among considered regimens, according 
to the scenario. In the base case hypothetical 
scenario, tenofovir/emtricitabine backbone 
loses almost 4.5 thousand patients in favour 
of abacavir/lamivudine, while the others re-
main quite stable. The largest increase in 
market share regards abacavir/lamivudine/
efavirenz-based therapy that passes to be as-
signed to 143 patients over three years in cur-
rent practice to a 14-fold larger group, under 
the tested hypothesis. Efavirenz is the most 
used drug in association to tenofovir/emtrici-
tabine, so the hypothesized market inversion 
between this regimen and that based on aba-
cavir/lamivudine may explain this result, 
combined with the basilar assumption that, 
on average, the third drugs prescription pre-
valence has to be maintained stable, indepen-
dently from the chosen backbone. Also regi-
mens consisting of abacavir/lamivudine 
added to lopinavir or darunavir present very 
strong (5-fold) market share increases.
The Italian prevalent HIV patients are more 
than 60 thousands, and more than two-thirds 
haven’t ever had a virologic failure. Every 
year in Italy about 39 thousands HIV patients 
are treated with a first line therapy, comprising 
strategies changed for tolerability reasons and 
excluding those patients receiving non-recom-
mended regimens (Table X). As shown in Ta-
ble XI, main market share modifications, in 
function of the base case scenario, follow the 
same trend of incident patients analysis, with 
abacavir/lamivudine backbone “gaining” 
8,900 patients, lost by tenofovir/emtricitabine. 
The differences are relatively less deep than in 
the incident patients analysis, since the distri-
bution of prevalent patients among backbones 
is slightly more equilibrated than for incident 
ones, (15%, 76%, 7% and 2% compared to 
9%, 83%, 8% and 0%, respectively for abaca-
Adverse event/
co-morbidities
Exam brief description
National 
unit cost (€)
Abacavir hypersensivity HLA-B*5701 test 56.23
Hepatic functioning Hepatic enzimes 8.52
Bilirubin level 2.54
Cardiovascular disease Electrocardiogram 12.03
Bone dysfunction Bone metabolism biomarkers 65.67
Lumbar spine and hip DEXA 33.45
Renal functioning Urine, creatinine, electrolytes 14.28
Dyslipidemia Lipids profile 7.24
Diabetes Glycaemia 1.55
Table VII. Unit costs of preventive and monitoring examinations. Source: Nom 
Spec, 2009 [20]
Patient (n.)
Residents 60,626,442
Incident HIV patients 3,445
Excluded for regimen 372
Year 1 target population 3,074
Deaths 52
Dropped-out 740
New incident patients 3,074
Year 2 target population 5,355
Deaths 81
Dropped-out 1,073
New incident patients 3,074
Year 3 target population 7,275
Cumulative patient-year 15,703
Table VIII. Flow for incident patients analysis
Regimens
Prescriptions (n.)
Current scenario Base case hypothetical scenario
ABC/3TC/RAL 21 45
ABC/3TC/DRV/r 306 1381
ABC/3TC/ATV/r 694 1,571
ABC/3TC/LPV/r 143 775
ABC/3TC/EFV 143 1,965
ABC/3TC/NVP 81 152
ABC/3TC/fAPV/r 21 15
TDF/FTC/RAL 98 64
TDF/FTC/DRV/r 3,306 1,996
TDF/FTC/ATV/r 3,383 2,271
TDF/FTC/LPV/r 1,143 1,121
TDF/FTC/EFV* 4,982 2,841
TDF/FTC/NVP 120 220
TDF/FTC/fAPV/r - 22
AZT/3TC/RAL - 10
AZT/3TC/DRV/r 61 296
AZT/3TC/ATV/r 101 336
AZT/3TC/LPV/r 776 166
AZT/3TC/EFV 103 421
AZT/3TC/NVP 204 33
AZT/3TC/fAPV/r 20 3
Table IX. Incident patients distribution among considered regimens
3TC = lamivudine; ABC = abacavir; ATV = atazanavir; AZT = zidovudine; DRV = darunavir; 
EFV = efavirenz; fAPV = fosamprenavir; FTC = emtricitabine; LPV = lopinavir; 
NVP = nevirapine; r = ritonavir; RAL = raltegravir; TDF = tenofovir
* Of which 2,959 in the current and 1,687 in the hypothetical receive co-formulation Atripla®
tability of the chosen first line regimen, in ad-
dition to routine cells count and viral load in-
vestigations. Based on guideline indications, 
a panel of experts identified which of these 
are typically carried out in an Italian real cli-
nical practice setting; only the determination 
of the allele associated to abacavir hypersen-
sitivity resulted generally adopted. Italian 
(and local) current tariff of direct sequencing 
is used as proxy of the real cost of materials 
and work time to perform HLA-B*5701 ge-
nomic typing (Table VII).
Pharmaceutical cost
Since considered drugs are supplied by the 
hospital pharmacy, real prices paid by a big 
hospital located in the northern part of Italy 
are used to inform the budget impact analysis 
[18]. They correspond to VAT-inclusive ex-
factory prices, net of hospital discounts ac-
cording to the negotiation process (Table VI). 
To calculate daily and monthly cost, dosage 
and frequency are taken from the Italian gui-
deline [1].
Monitoring cost
Guidelines strongly recommend carrying out 
periodical exams to evaluate non-infective 
co-morbidity onset in HIV patients, especial-
ly if they are treated with specifically toxic 
drugs. These recommendations have been 
reviewed by a panel of experts that drive us 
to the understanding of which tests and how 
often are usually performed in real clinical 
practice.
The following list summarizes the monitored 
co-morbidities and the regimen-specific fre-
quency adopted for our model:
 - Hepatopathy: liver enzymes dosing 2 ti-
mes/year for all patients; bilirubin level 
assessment 3 times/year for patients re-
ceiving atazanavir;
 - Cardiovascular disease: electrocardio-
graphy 1 time/year for all patients;
 - Ostheopathy: analysis of bone metabo-
lism biomarkers (serum osteocalcin, pa-
rathyroid hormone, telopeptide, phospho-
rus and calcium) 1 time/year for patients 
receiving tenofovir; dual energy x-ray ab-
sorptiometry (DEXA) scan of lumbar spi-
ne and hip, 2 times/year for all patients;
 - Renal functioning: complete urine exam, 
creatinine, blood electrolytes 1 time/year 
for all patients, 2 times/year for patients 
receiving atazanavir or lopinavir, 3 times/
year for those receiving tenofovir;
 - Dyslipidemia: lipid profile 1 time/year 
for all patients, 2 times/year for patients 
receiving abacavir, 3 times/year for those 
receiving a protease inhibitor;
 - Diabetes: glycaemia assessment 1 time/
year for all patients, 2 times/year for pa-
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vir/lamivudine; tenofovir/emtricitabine; zido-
vudine/lamivudine and tenofovir/lamivudine).
Cost results
Table XII presents annual cost for each consi-
dered regimen, divided into pharmaceutical, 
preventive and monitoring expenses, listed in 
ascending order of total cost. Pharmaceutical 
cost represents the most important cost item 
and is responsible of the major cost difference 
among regimens; monitoring expenses vary in 
Patient (n.)
Residents 60,626,442
Prevalent HIV patients 61,175
No virologic failure patients 43,373
Excluded for regimen 4,338
Annual target population 39,035
Table X. Flow for prevalent patients analysis
Regimens
Prescriptions (n.)
Current scenario
Base case 
hypothetical scenario
ABC/3TC/RAL 102 256
ABC/3TC/DRV/r 411 1.351
ABC/3TC/ATV/r 2,244 3.429
ABC/3TC/LPV/r 810 2.154
ABC/3TC/EFV 903 5.190
ABC/3TC/NVP 791 1.642
ABC/3TC/fAPV/r 493 654
TDF/FTC/RAL 560 364
TDF/FTC/DRV/r 3,118 1.920
TDF/FTC/ATV/r 6,624 4.874
TDF/FTC/LPV/r 3,628 3.062
TDF/FTC/EFV 12,470 7.376
TDF/FTC/NVP 2,287 2.334
TDF/FTC/fAPV/r 1,096 930
AZT/3TC/RAL 19 50
AZT/3TC/DRV/r 31 262
AZT/3TC/ATV/r 126 666
AZT/3TC/LPV/r 1,107 418
AZT/3TC/EFV 302 1.008
AZT/3TC/NVP 1,157 319
AZT/3TC/fAPV/r 107 127
TDF/3TC/RAL 0 11
TDF/3TC/DRV/r 32 60
TDF/3TC/ATV/r 127 151
TDF/3TC/LPV/r 184 95
TDF/3TC/EFV 127 229
TDF/3TC/NVP 134 73
TDF/3TC/fAPV/r 44 29
Table XI. Prevalent patients distribution among considered regimens
3TC = lamivudine; ABC = abacavir; ATV = atazanavir; AZT = zidovudine; DRV = darunavir; 
EFV = efavirenz; fAPV = fosamprenavir; FTC = emtricitabine; LPV = lopinavir; 
NVP = nevirapine; r = ritonavir; RAL = raltegravir; TDF = tenofovir
* Of which 85% receive co-formulation Atripla®
tients receiving abacavir, 3 times/year for 
those receiving a protease inhibitor;
Unit cost for monitoring exams is taken from 
current National and local reimbursement ta-
riffs [20] (Table VII).
RESULTS
Patients results
Every year in Italy, about three thousand pa-
tients are estimated to start HAART, of which 
2,300 stay on the same first line therapy for 
the following year, and about 1,900 for the 
third consecutive year. The incidence with 
accumulation approach leads to the gathering 
of a target population of 7,300 patients, for 
the third year of the analysis. Table VIII sum-
marizes the incident patient flow over time; a 
total of 15,703 patients have been treated for 
1 year. Table IX shows the patient distribu-
tion among considered regimens, according 
to the scenario. In the base case hypothetical 
scenario, tenofovir/emtricitabine backbone 
loses almost 4.5 thousand patients in favour 
of abacavir/lamivudine, while the others re-
main quite stable. The largest increase in 
market share regards abacavir/lamivudine/
efavirenz-based therapy that passes to be as-
signed to 143 patients over three years in cur-
rent practice to a 14-fold larger group, under 
the tested hypothesis. Efavirenz is the most 
used drug in association to tenofovir/emtrici-
tabine, so the hypothesized market inversion 
between this regimen and that based on aba-
cavir/lamivudine may explain this result, 
combined with the basilar assumption that, 
on average, the third drugs prescription pre-
valence has to be maintained stable, indepen-
dently from the chosen backbone. Also regi-
mens consisting of abacavir/lamivudine 
added to lopinavir or darunavir present very 
strong (5-fold) market share increases.
The Italian prevalent HIV patients are more 
than 60 thousands, and more than two-thirds 
haven’t ever had a virologic failure. Every 
year in Italy about 39 thousands HIV patients 
are treated with a first line therapy, comprising 
strategies changed for tolerability reasons and 
excluding those patients receiving non-recom-
mended regimens (Table X). As shown in Ta-
ble XI, main market share modifications, in 
function of the base case scenario, follow the 
same trend of incident patients analysis, with 
abacavir/lamivudine backbone “gaining” 
8,900 patients, lost by tenofovir/emtricitabine. 
The differences are relatively less deep than in 
the incident patients analysis, since the distri-
bution of prevalent patients among backbones 
is slightly more equilibrated than for incident 
ones, (15%, 76%, 7% and 2% compared to 
9%, 83%, 8% and 0%, respectively for abaca-
Adverse event/
co-morbidities
Exam brief description
National 
unit cost (€)
Abacavir hypersensivity HLA-B*5701 test 56.23
Hepatic functioning Hepatic enzimes 8.52
Bilirubin level 2.54
Cardiovascular disease Electrocardiogram 12.03
Bone dysfunction Bone metabolism biomarkers 65.67
Lumbar spine and hip DEXA 33.45
Renal functioning Urine, creatinine, electrolytes 14.28
Dyslipidemia Lipids profile 7.24
Diabetes Glycaemia 1.55
Table VII. Unit costs of preventive and monitoring examinations. Source: Nom 
Spec, 2009 [20]
Patient (n.)
Residents 60,626,442
Incident HIV patients 3,445
Excluded for regimen 372
Year 1 target population 3,074
Deaths 52
Dropped-out 740
New incident patients 3,074
Year 2 target population 5,355
Deaths 81
Dropped-out 1,073
New incident patients 3,074
Year 3 target population 7,275
Cumulative patient-year 15,703
Table VIII. Flow for incident patients analysis
Regimens
Prescriptions (n.)
Current scenario Base case hypothetical scenario
ABC/3TC/RAL 21 45
ABC/3TC/DRV/r 306 1381
ABC/3TC/ATV/r 694 1,571
ABC/3TC/LPV/r 143 775
ABC/3TC/EFV 143 1,965
ABC/3TC/NVP 81 152
ABC/3TC/fAPV/r 21 15
TDF/FTC/RAL 98 64
TDF/FTC/DRV/r 3,306 1,996
TDF/FTC/ATV/r 3,383 2,271
TDF/FTC/LPV/r 1,143 1,121
TDF/FTC/EFV* 4,982 2,841
TDF/FTC/NVP 120 220
TDF/FTC/fAPV/r - 22
AZT/3TC/RAL - 10
AZT/3TC/DRV/r 61 296
AZT/3TC/ATV/r 101 336
AZT/3TC/LPV/r 776 166
AZT/3TC/EFV 103 421
AZT/3TC/NVP 204 33
AZT/3TC/fAPV/r 20 3
Table IX. Incident patients distribution among considered regimens
3TC = lamivudine; ABC = abacavir; ATV = atazanavir; AZT = zidovudine; DRV = darunavir; 
EFV = efavirenz; fAPV = fosamprenavir; FTC = emtricitabine; LPV = lopinavir; 
NVP = nevirapine; r = ritonavir; RAL = raltegravir; TDF = tenofovir
* Of which 2,959 in the current and 1,687 in the hypothetical receive co-formulation Atripla®
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a narrow range (from 69 euro for zidovudine/
lamivudine/efavirenz to 188 euro for tenofo-
vir/emtricitabine/atazanavir), whereas preven-
tive cost is applied only to abacavir-based re-
gimens. As shown in the Table, NNRTI-based 
regimens are cheapest; among these, the rank 
cation: the minimum scenario forecasts that 
only 20% of patients present low viral loads; 
in the maximum one this portion is increa-
sed to 50%. Budget Impact related to inci-
dent patients varies between a saving of 850 
thousand euro and of 3.3 million euro, re-
spectively for minimum and maximum sce-
nario. For prevalent patients these figures 
are equal to 922 thousand euro and 7.3 mil-
lion euro.
DISCUSSION AND CONCLUSIONS
Since the advent of triple therapy in the mid-
1990s, the clinical course of HIV infection is 
changed, reducing the disease progression, 
the mortality and the incidence of opportuni-
stic infections: HIV patients, fortunately, live 
longer and better, especially in developed 
countries.
Current 
scenario
Base case 
hypothetical scenario
Patients (n.) 15,703 15,703
Backbone cost (€) 81,110,391 78,941,216
Third drug cost (€) 59,465,733 59,414,689
Complete regimen cost (€) 140,576,123 138,355,905
Preventive exams cost (€) 46,508 194,952
Monitoring investigations (€) 2,542,719 2,152,115
Total cost (€) 143,165,351 140,702,973
Budget impact H vs C (€) -2.462.379
(%) -1.7
Table XIII. Incident patients analysis three years-cumulative Budget Impact results
Current scenario
Base case 
hypothetical scenario
Budget Impact H vs C
€ %
Year 1 Patients (n.) 3,074 3.074 -461,546 -1.65
Total cost (€) 28,028,743 27,567,197
Year 2 Patients (n.) 5,355 5,355 -840,805 -1.72
Total cost (€) 48,818,790 47,977,986
Year 3 Patients (n.) 7,275 7,275 -1,160,028 -1.75
Total cost (€) 66,317,818 65,157,790
Table XIV. Incident patients analysis single year Budget Impact results
Current 
scenario
Base case 
hypothetical scenario
Patients (n.) 39,035 39,035
Backbone cost (€) 200,232,519 195,999,766
Third drug cost (€) 139,480,733 139,306,748
Complete regimen cost (€) 339,713,253 335,306,513
Monitoring investigations (€) 6.057.094 5,296,737
Total cost (€) 345.770.346 340,603,250
Budget impact 
H vs C
(€) -5,167,096
(%) -1.5%
Table XV. Prevalent patients analysis annual Budget Impact results
Current 
scenario
Minimum 
hypothetical 
scenario
BI H vs C
Maximum 
hypothetical 
scenario
BI H vs C
3-year incident patients
Patients receiving ABC/3TC (n.) 1,409 2,952 +1,543 7,380 +5,971
Total cost (€) 143,165,351 142,315,350 -850,001 139,896,784 -3,268,568
Prevalent patients
Patients receiving ABC/3TC (n.) 5,754 7,339 +1,585 18,346 +12,592
Total cost (€) 345,770,346 344,847,853 -922,493 338,480,949 -7,289,398
Table XVI. Incident and prevalent patients analyses running on minimum and maximum hypothetical scenarios
ABC = abacavir; C = current; H = hypothetical; 3TC = lamivudine
of the backbones in ascending order of annual 
cost corresponds to zidovudine/lamivudine, 
tenofovir/lamivudine, abacavir/lamivudine, 
and tenofovir/emtricitabine. The lower moni-
toring cost of abacavir-based regimens (ran-
ging between 78 and 108 euro according to 
the third drug) with respect to tenofovir/emtri-
citabine ones (ranging between 163 and 188 
euro) is partly offset by their preventive costs 
(€ 56). The remaining monitoring cost saving, 
added to the averagely lower pharmaceutical 
cost (for backbone € 4,846 vs € 5,340) is the 
net saving estimate, linked to the use of abaca-
vir/lamivudine compared to the other first 
choice backbone. For the first year of therapy 
the total cost of these two strategies ranges 
between 7,269 and 11,324 euro for abacavir/
lamivudine and between 7,792 and 11,847 
euro for tenofovir/emtricitabine; the differen-
ce slightly increases in following years becau-
se of the absence of preventive cost.
Regimens
Pharmaceutical costs (€) Preventive 
exams (€)
Monitoring 
investigations (€)
Total cost (€)
Backbone Third drug Year 1 Following years
AZT/3TC/NVP 3,814.25 2,288.55 68.87 6,171.67 6,171.67
AZT/3TC/EFV 3,814.25 2,609.75 68.87 6,492.87 6,492.87
TDF/3TC/NVP 4,420.52 2,288.55 163.10 6,872.17 6,872.17
TDF/3TC/EFV 4,420.52 2,609.75 163.10 7,193.37 7,193.37
ABC/3TC/NVP 4,846.11 2,288.55 56.23 77.66 7,268.55 7,212.32
ABC/3TC/EFV 4,846.11 2,609.75 56.23 77.66 7,589.75 7,533.52
TDF/FTC/NVP 5,339.95 2,288.55 163.10 7,791.60 7,791.60
TDF/FTC/EFV 5,339.95 2,609.75 163.10 8,112.80 8,112.80
Co-form. TDF/FTC/EFV 5,299.80 2,649.90 163.10 8,112.80 8,112.80
AZT/3TC/LPV/r 3,814.25 4,352.26 100.73 8,267.24 8,267.24
AZT/3TC/ATV/r 3,814.25 4,354.09 108.35 8,276.69 8,276.69
AZT/3TC/fAPV/r 3,814.25 4,452.27 86.45 8,352.97 8,352.97
AZT/3TC/DRV/r 3,814.25 4,542.79 86.45 8,443.49 8,443.49
TDF/3TC/LPV/r 4,420.52 4,352.26 180.68 8,953.46 8,953.46
TDF/3TC/ATV/r 4,420.52 4,354.09 188.30 8,962.91 8,962.91
TDF/3TC/fAPV/r 4,420.52 4,452.27 180.68 9,053.47 9,053.47
TDF/3TC/DRV/r 4,420.52 4,542.79 180.68 9,143.99 9,143.99
ABC/3TC/LPV/r 4,846.11 4,352.26 56.23 100.73 9,355.33 9,299.10
ABC/3TC/ATV/r 4,846.11 4,354.09 56.23 108.35 9,364.78 9,308.55
ABC/3TC/fAPV/r 4,846.11 4,452.27 56.23 86.45 9,441.06 9,384.83
ABC/3TC/DRV/r 4,846.11 4,542.79 56.23 86.45 9,531.58 9,475.35
TDF/FTC/LPV/r 5,339.95 4,352.26 180.68 9,872.89 9,872.89
TDF/FTC/ATV/r 5,339.95 4,354.09 188.30 9,882.34 9,882.34
TDF/FTC/fAPV/r 5,339.95 4,452.27 180.68 9,972.90 9,972.90
TDF/FTC/DRV/r 5,339.95 4,542.79 180.68 10,063.42 10,063.42
AZT/3TC/RAL 3,814.25 6,343.70 68.87 10,226.82 10,226.82
TDF/3TC/RAL 4,420.52 6,343.70 163.10 10,927.32 10,927.32
ABC/3TC/RAL 4,846.11 6,343.70 56.23 77.66 11,323.70 11,267.47
TDF/FTC/RAL 5,339.95 6,343.70 163.10 11,846.75 11,846.75
Table XII. Annual cost for regimen; strategies are listed in ascending order of total cost
3TC = lamivudine; ABC = abacavir; ATV = atazanavir; AZT = zidovudine; DRV = darunavir; EFV = efavirenz; fAPV = fosamprenavir; FTC = emtricitabine; 
LPV = lopinavir; NVP = nevirapine; r = ritonavir; RAL = raltegravir; TDF = tenofovir
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cation: the minimum scenario forecasts that 
only 20% of patients present low viral loads; 
in the maximum one this portion is increa-
sed to 50%. Budget Impact related to inci-
dent patients varies between a saving of 850 
thousand euro and of 3.3 million euro, re-
spectively for minimum and maximum sce-
nario. For prevalent patients these figures 
are equal to 922 thousand euro and 7.3 mil-
lion euro.
DISCUSSION AND CONCLUSIONS
Since the advent of triple therapy in the mid-
1990s, the clinical course of HIV infection is 
changed, reducing the disease progression, 
the mortality and the incidence of opportuni-
stic infections: HIV patients, fortunately, live 
longer and better, especially in developed 
countries.
Current 
scenario
Base case 
hypothetical scenario
Patients (n.) 15,703 15,703
Backbone cost (€) 81,110,391 78,941,216
Third drug cost (€) 59,465,733 59,414,689
Complete regimen cost (€) 140,576,123 138,355,905
Preventive exams cost (€) 46,508 194,952
Monitoring investigations (€) 2,542,719 2,152,115
Total cost (€) 143,165,351 140,702,973
Budget impact H vs C (€) -2.462.379
(%) -1.7
Table XIII. Incident patients analysis three years-cumulative Budget Impact results
Current scenario
Base case 
hypothetical scenario
Budget Impact H vs C
€ %
Year 1 Patients (n.) 3,074 3.074 -461,546 -1.65
Total cost (€) 28,028,743 27,567,197
Year 2 Patients (n.) 5,355 5,355 -840,805 -1.72
Total cost (€) 48,818,790 47,977,986
Year 3 Patients (n.) 7,275 7,275 -1,160,028 -1.75
Total cost (€) 66,317,818 65,157,790
Table XIV. Incident patients analysis single year Budget Impact results
Current 
scenario
Base case 
hypothetical scenario
Patients (n.) 39,035 39,035
Backbone cost (€) 200,232,519 195,999,766
Third drug cost (€) 139,480,733 139,306,748
Complete regimen cost (€) 339,713,253 335,306,513
Monitoring investigations (€) 6.057.094 5,296,737
Total cost (€) 345.770.346 340,603,250
Budget impact 
H vs C
(€) -5,167,096
(%) -1.5%
Table XV. Prevalent patients analysis annual Budget Impact results
Current 
scenario
Minimum 
hypothetical 
scenario
BI H vs C
Maximum 
hypothetical 
scenario
BI H vs C
3-year incident patients
Patients receiving ABC/3TC (n.) 1,409 2,952 +1,543 7,380 +5,971
Total cost (€) 143,165,351 142,315,350 -850,001 139,896,784 -3,268,568
Prevalent patients
Patients receiving ABC/3TC (n.) 5,754 7,339 +1,585 18,346 +12,592
Total cost (€) 345,770,346 344,847,853 -922,493 338,480,949 -7,289,398
Table XVI. Incident and prevalent patients analyses running on minimum and maximum hypothetical scenarios
ABC = abacavir; C = current; H = hypothetical; 3TC = lamivudine
Budget impact
Table XIII shows the financial impact that 
Italian National Health Service may expect if 
for the next three-year period patients star-
ting HAART were treated according to the 
base case hypothetical scenario. The pre-
scriptions switch from tenofovir/emtricita-
bine to abacavir/lamivudine for a portion of 
new patients for which this regimen repre-
sents a first choice treatment (HLA-B*5701 
allele negative and viral load < 100,000 co-
pies) induces a cost saving, mainly due to the 
lower acquisition cost, of almost 2.5 million 
euro. The total cost for preventive exams is, 
obviously, slightly higher in the hypothetical 
scenario, since only abacavir hypersensitivi-
ty test is considered in the analysis, whereas 
monitoring expenses are about 400 thousand 
euro higher in the current setting.
As shown in Tabel XIV, where BIM results 
are reported for each single year, savings 
grow with increasing numerousness of the 
target pool; the same holds true in regional 
contexts: Lombardia presents highest cost 
saving; at the opposite Valle d’Aosta, with its 
cumulative 46 patients (data not shown).
For the simulation running on the prevalent 
population, the considerations that can be 
drawn are similar: the increase, in the past 
years, of abacavir/lamivudine market shares 
could now induce a net annual cost saving of 
more than 5 million euro (Table XV). Table 
XVI shows how results change according to 
the variability of tested prescriptions modifi-
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Compared to our model-estimated mean 
HAART cost (€ 8,952), 5 out of seven aba-
cavir/lamivudine (€ 7,135-11,190) and teno-
fovir/emtricitabine (€ 7,629-11,684) based 
strategies are more expensive that this value, 
whereas for tenofovir/lamivudine (€ 6,709 
- 10,764) and for zidovudine/lamivudine (€ 
6,103 - 10,158) this figure decreases to 2 and 
1, respectively. Despite the growing need for 
health care resources rationalization, these 
cheaper backbones are the least prescribed 
ones in Italy, with market share lower than 
2% for zidovudine/lamivudine and of about 
7-8% for the other one.
In order to explain this apparently irrational 
condition it’s necessary to draw the attention 
on the other term of the earlier mentioned 
crucial union: the appropriateness of care. Zi-
dovudine/lamivudine-based regimens are re-
commended by the guideline only as an alter-
native choice, for lower effectiveness, worse 
toxicity profile, and minor genetic barrier. On 
the other hand, tenofovir and lamivudine are 
not available in co-formulation, whereas gui-
delines strongly prompt for lower pill burden 
regimens.
Restricting the comparison to the only two 
backbones recommended as first choice, our 
model estimates a lower cost for abacavir/
lamivudine compared to tenofovir/emtricita-
bine; this leads to a potential cost saving of 
almost 2,5 million euro for incident patients 
over a cumulative three-year period and more 
than 5 million euro for the almost 40 thousand 
prevalent patients, against a drastic increa-
se of its market share. This potential result 
strongly depends on the number of patients 
that hypothetically switches from tenofovir/
emtricitabine to abacavir/lamivudine and this 
value represents an uncertain parameter, in-
fluenced by many factors, also linked to pre-
scription habits and individual experiences. 
In order to assess the impact of this uncer-
tainty in our analysis, we provided minimum 
and maximum settings, estimating a potential 
cost saving ranging, for incident patients, 
between 850 thousand and 3,3 million euro, 
for the share of patients receiving abacavir/
lamivudine moving from 19% to 47% of the 
total market. However, to turn this potential 
saving into something real, in order to create 
the conditions for the National Health Servi-
ce to reallocate efficiently the resources, it’s 
important that abacavir/lamivudine repre-
sents an appropriate choice of treatment, and 
not only a convenient option, especially with 
respect to tenofovir/emtricitabine.
During the last years, increasing attention has 
been given to “complementary” factors, besi-
des the “traditional” effectiveness, measured 
by lymphocyte count or viral load. Accepta-
Italian [1] and international guidelines 
[17,21] state that HAART is indicated for all 
HIV individuals, with strong recommenda-
tion for those with a CD4 count <500 cells/
mm3. In general, this leads to a very large 
pool of patients receiving treatment and to 
a consequent high overall expenditure. For 
many national health care services, especial-
ly in the case of contemporary reduction in 
health care funding as it happens in Italy, 
this may not be affordable. Furthermore, 
other issues regarding patient management 
have recently changed; for example new 
guidelines recommend PEGylated interfe-
ron or ribavirin for the treatment of HCV 
co-infection [17] and new expensive drugs, 
such as raltegravir, darunavir, etravirine, ma-
raviroc, have begun to spread; as a results, 
the cost of HIV care is bound to further in-
crease. Rizzardini and colleagues conducted 
a retrospective, observational, longitudinal 
study, involving 483 patients followed at 
the First Infectious Disease Department of 
“L Sacco” Hospital in Milan (Lombardia-
Italy) in 2007–2009 [22]. Despite the impro-
vement of the mean CD4+ cell count over 
the study period, the total cost increased by 
5% in 2008 and by 25% in 2009. This was 
mainly due to the increase of the frequency 
of hospital admission and of the prevalence 
of use of expensive regimens based on ral-
tegravir, darunavir, etravirine, or maraviroc 
(means total cost € 18,490 vs. 11,100 for pa-
tients not prescribed new drugs). Even if the 
cost for non-HIV drugs and for outpatient 
visits slightly decreased, this trend appears 
not sufficient to offset the increase in other 
expenditure items.
This study underlines that to achieve immu-
nological improvement, founding has to be 
augmented, at least in the short term. The 
resulting economic burden induces health 
care providers to increasingly focus their at-
tention on the crucial union between cost and 
the appropriateness of care. In terms of cost, 
the annual mean HAART cost (€ 8,952) esti-
mated by our model is quite consistent with 
that emerged from the study by Rizzardini et 
al. (€ 8,471). Since the pharmaceutical costs 
are taken from the same data source (Hospi-
tal “Sacco” in Milan), this consistence shows 
a comparable distribution of patients among 
strategies with different economic burden. 
Instead, the total cost estimated by Rizzardi-
ni et al. is higher than the value here found (€ 
9,117 vs. 11,735), since it comprised also ho-
spital admission and outpatient visits, where-
as in the present analysis the routine clinical 
management of the patient is not considered, 
aiming to focus on differential and regimen-
dependent costs only. 
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increased rate of cardiovascular events with 
the use of this drug [25]. A two recent meta-
analysis of randomized trials have almost de-
finitively clarified that no association betwe-
en MI and abacavir exists [33,34].
The cost saving estimated is conservative sin-
ce the impact of co-morbidities is entered in 
the model only as cost of monitoring exami-
nations to prevent/evaluate these conditions, 
not also as side effect management expen-
diture. Furthermore, only abacavir-related 
preventive test is considered among cost 
items. Other possible preventive exams, like 
the renal function evaluation before starting 
tenofovir-based therapies, the investigation of 
mutations on binding site between raltegra-
vir and integrase-enzyme, psychiatric illness 
anamnesis in case of efavirenz use are recom-
mended by guidelines. We excluded these 
costs from the modeling because of their poor 
adoption in the real clinical practice.
Some limitations of the presented analysis 
are related to the epidemiologic data; the 
estimated prevalence of HIV patients is lo-
wer than that usually found in registries/da-
tabases, probably due to the selected target: 
our model is fed only with treated patients, 
whereas in the epidemiologic source, gene-
rally, the number of all prevalent patients is 
reported. An assumed compliance of 100% 
may underestimate our pool of patients, iden-
tified on basis of drug prescriptions; on the 
other hand, it was not possible to separate 
drug sales allocated to hepatitis care from 
those for HIV treatment and this may produ-
ce an overestimate of the cohort. Furthermo-
re, for practical reasons, patients receiving 
heroic or not-recommended regimens based 
on resistance test have been excluded from 
the analysis, despite their use in real clinical 
practice. These limitations notwithstanding, 
our model results indicate that the evaluated 
change in prescription pattern, increasing 
abacavir/lamivudine market share at the ex-
pense of other backbones, represents a choice 
of convenience and appropriateness. It makes 
the objective to guarantee the administration 
of an equally effective and equally or more 
safe regimen to naive patients possible, with 
a resources release that may be dedicated to 
more severe/multi-resistant/problematic pa-
tients.
ble long-term safety profiles, minimal ma-
nagement requirements (thermostability and 
low pill burden) and safety in pregnant wo-
men are now main key issues, under equal ef-
fectiveness assumption. For the second item, 
for example, tenofovir/emtricitabine presents 
the advantage to be available, with efavirenz, 
in a unique tablet formulation. It’s conside-
red the gold standard for a good portion of 
the scientific community; however not every 
patient may receive this regimen: efavirenz 
in currently not recommended for use in pre-
gnancy, and some safety concerns referring 
to tenofovir are under an active debate.
Two trials found greater decreases in bone 
mineral density (BMD) with tenofovir/
emtricitabine than with abacavir/lamivudine-
based treatment [23,24]. To date, only one 
trial recorded BMD data among virologically 
suppressed HIV patients [25] and its results 
highlighted significant reductions in hip and 
spine BMD. However, the clinical significan-
ce of these differences remains uncertain, as 
they were not correlated to more fractures. For 
renal complications onset, another relevant 
safety concern, this trial reported no signifi-
cant between-group difference for glomerular 
filtration rate and other common parameters. 
On the contrary, a recent meta-analysis com-
paring tenofovir-containing with tenofovir 
not-containing regimens shows a small but 
statistically significant loss of renal function 
associated to tenofovir [26]. Also abacavir/
lamivudine is not immune from safety trou-
bles; the association between abacavir ad-
ministration and myocardial infarction (MI) 
has been heavily debated. Briefly, this asso-
ciation has been found in two cohort studies 
[27,28]; whereas data from the AIDS Clinical 
Trial Group [29] on naïve patients, short and 
long-term results from ACTG A5001 [30], 
the Veterans Health Administration’s Clinical 
Case Registry [31], and a study conducted on 
the HIV French Hospital Database with the 
case-control methodology [32] did not find a 
significant causal relationship between aba-
cavir and MI. In randomized controlled trials 
comparing ABC with tenofovir, no increase 
in MI rate has been detected [2-4]. Only the 
STEAL-study, in which patients assigned to 
the abacavir treatment had higher prevalen-
ce of cardiovascular risk factors, detected an 
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